Cargando…
Hospitalization and Mortality in Patients With Heart Failure Treated With Sacubitril/Valsartan vs. Enalapril: A Real-World, Population-Based Study
Background: The effect of sacubitril/valsartan on survival and hospitalization risk in older patients with heart failure has not been explored. We aimed to investigate the risk of hospitalization and mortality with the use of sacubitril/valsartan vs. enalapril in patients with heart failure. Methods...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7855850/ https://www.ncbi.nlm.nih.gov/pubmed/33553256 http://dx.doi.org/10.3389/fcvm.2020.602363 |
_version_ | 1783646205266362368 |
---|---|
author | Pathadka, Swathi Yan, Vincent K. C. Li, Xue Tse, Gary Wan, Eric Y. F. Lau, Hayden Lau, Wallis C. Y. Siu, David C. W. Chan, Esther W. Wong, Ian C. K. |
author_facet | Pathadka, Swathi Yan, Vincent K. C. Li, Xue Tse, Gary Wan, Eric Y. F. Lau, Hayden Lau, Wallis C. Y. Siu, David C. W. Chan, Esther W. Wong, Ian C. K. |
author_sort | Pathadka, Swathi |
collection | PubMed |
description | Background: The effect of sacubitril/valsartan on survival and hospitalization risk in older patients with heart failure has not been explored. We aimed to investigate the risk of hospitalization and mortality with the use of sacubitril/valsartan vs. enalapril in patients with heart failure. Methods: This was a population-based cohort study using the Hong Kong-wide electronic healthcare database. Patients diagnosed with heart failure and newly prescribed sacubitril/valsartan or enalapril between July 2016 and June 2019 were included. The risk of primary composite outcome of cardiovascular mortality or heart failure-related hospitalization, all-cause hospitalization, heart failure-related hospitalization, cardiovascular mortality and all-cause mortality were compared using Cox regression with inverse probability treatment weighting. Additional analysis was conducted by age stratification. Results: Of the 44,503 patients who received sacubitril/valsartan or enalapril, 3,237 new users (sacubitril/valsartan, n = 1,056; enalapril, n = 2,181) with a diagnosis of heart failure were identified. Compared with enalapril, sacubitril/valsartan users were associated with a lower risk of primary composite outcome [hazard ratio (HR) 0.58; 95% confidence interval (CI), 0.45–0.75], heart failure-related hospitalization (HR 0.59; 95% CI, 0.45–0.77), all-cause mortality (HR 0.51; 95% CI, 0.36–0.74) and borderline non-significant reductions in all-cause hospitalization (HR 0.85; 95% CI, 0.70–1.04) and cardiovascular mortality (HR 0.63; 95% CI, 0.39–1.02). The treatment effect of sacubitril/valsartan remains unaltered in the patient subgroup age ≥ 65 years (73%). Conclusions: In real-world settings, sacubitril/valsartan was associated with improved survival and reduced heart failure-related hospitalization compared to enalapril in Asian patients with heart failure. The effectiveness remains consistent in the older population. |
format | Online Article Text |
id | pubmed-7855850 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78558502021-02-04 Hospitalization and Mortality in Patients With Heart Failure Treated With Sacubitril/Valsartan vs. Enalapril: A Real-World, Population-Based Study Pathadka, Swathi Yan, Vincent K. C. Li, Xue Tse, Gary Wan, Eric Y. F. Lau, Hayden Lau, Wallis C. Y. Siu, David C. W. Chan, Esther W. Wong, Ian C. K. Front Cardiovasc Med Cardiovascular Medicine Background: The effect of sacubitril/valsartan on survival and hospitalization risk in older patients with heart failure has not been explored. We aimed to investigate the risk of hospitalization and mortality with the use of sacubitril/valsartan vs. enalapril in patients with heart failure. Methods: This was a population-based cohort study using the Hong Kong-wide electronic healthcare database. Patients diagnosed with heart failure and newly prescribed sacubitril/valsartan or enalapril between July 2016 and June 2019 were included. The risk of primary composite outcome of cardiovascular mortality or heart failure-related hospitalization, all-cause hospitalization, heart failure-related hospitalization, cardiovascular mortality and all-cause mortality were compared using Cox regression with inverse probability treatment weighting. Additional analysis was conducted by age stratification. Results: Of the 44,503 patients who received sacubitril/valsartan or enalapril, 3,237 new users (sacubitril/valsartan, n = 1,056; enalapril, n = 2,181) with a diagnosis of heart failure were identified. Compared with enalapril, sacubitril/valsartan users were associated with a lower risk of primary composite outcome [hazard ratio (HR) 0.58; 95% confidence interval (CI), 0.45–0.75], heart failure-related hospitalization (HR 0.59; 95% CI, 0.45–0.77), all-cause mortality (HR 0.51; 95% CI, 0.36–0.74) and borderline non-significant reductions in all-cause hospitalization (HR 0.85; 95% CI, 0.70–1.04) and cardiovascular mortality (HR 0.63; 95% CI, 0.39–1.02). The treatment effect of sacubitril/valsartan remains unaltered in the patient subgroup age ≥ 65 years (73%). Conclusions: In real-world settings, sacubitril/valsartan was associated with improved survival and reduced heart failure-related hospitalization compared to enalapril in Asian patients with heart failure. The effectiveness remains consistent in the older population. Frontiers Media S.A. 2021-01-20 /pmc/articles/PMC7855850/ /pubmed/33553256 http://dx.doi.org/10.3389/fcvm.2020.602363 Text en Copyright © 2021 Pathadka, Yan, Li, Tse, Wan, Lau, Lau, Siu, Chan and Wong. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cardiovascular Medicine Pathadka, Swathi Yan, Vincent K. C. Li, Xue Tse, Gary Wan, Eric Y. F. Lau, Hayden Lau, Wallis C. Y. Siu, David C. W. Chan, Esther W. Wong, Ian C. K. Hospitalization and Mortality in Patients With Heart Failure Treated With Sacubitril/Valsartan vs. Enalapril: A Real-World, Population-Based Study |
title | Hospitalization and Mortality in Patients With Heart Failure Treated With Sacubitril/Valsartan vs. Enalapril: A Real-World, Population-Based Study |
title_full | Hospitalization and Mortality in Patients With Heart Failure Treated With Sacubitril/Valsartan vs. Enalapril: A Real-World, Population-Based Study |
title_fullStr | Hospitalization and Mortality in Patients With Heart Failure Treated With Sacubitril/Valsartan vs. Enalapril: A Real-World, Population-Based Study |
title_full_unstemmed | Hospitalization and Mortality in Patients With Heart Failure Treated With Sacubitril/Valsartan vs. Enalapril: A Real-World, Population-Based Study |
title_short | Hospitalization and Mortality in Patients With Heart Failure Treated With Sacubitril/Valsartan vs. Enalapril: A Real-World, Population-Based Study |
title_sort | hospitalization and mortality in patients with heart failure treated with sacubitril/valsartan vs. enalapril: a real-world, population-based study |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7855850/ https://www.ncbi.nlm.nih.gov/pubmed/33553256 http://dx.doi.org/10.3389/fcvm.2020.602363 |
work_keys_str_mv | AT pathadkaswathi hospitalizationandmortalityinpatientswithheartfailuretreatedwithsacubitrilvalsartanvsenalaprilarealworldpopulationbasedstudy AT yanvincentkc hospitalizationandmortalityinpatientswithheartfailuretreatedwithsacubitrilvalsartanvsenalaprilarealworldpopulationbasedstudy AT lixue hospitalizationandmortalityinpatientswithheartfailuretreatedwithsacubitrilvalsartanvsenalaprilarealworldpopulationbasedstudy AT tsegary hospitalizationandmortalityinpatientswithheartfailuretreatedwithsacubitrilvalsartanvsenalaprilarealworldpopulationbasedstudy AT wanericyf hospitalizationandmortalityinpatientswithheartfailuretreatedwithsacubitrilvalsartanvsenalaprilarealworldpopulationbasedstudy AT lauhayden hospitalizationandmortalityinpatientswithheartfailuretreatedwithsacubitrilvalsartanvsenalaprilarealworldpopulationbasedstudy AT lauwalliscy hospitalizationandmortalityinpatientswithheartfailuretreatedwithsacubitrilvalsartanvsenalaprilarealworldpopulationbasedstudy AT siudavidcw hospitalizationandmortalityinpatientswithheartfailuretreatedwithsacubitrilvalsartanvsenalaprilarealworldpopulationbasedstudy AT chanestherw hospitalizationandmortalityinpatientswithheartfailuretreatedwithsacubitrilvalsartanvsenalaprilarealworldpopulationbasedstudy AT wongianck hospitalizationandmortalityinpatientswithheartfailuretreatedwithsacubitrilvalsartanvsenalaprilarealworldpopulationbasedstudy |